OutSee, an AI-enabled genomics and drug discovery company, has closed a £2.5 million seed funding round and signed a strategic agreement with o2h discovery to begin a collaborative drug discovery programme around OutSee’s lead drug target candidate.
Under the partnership, OutSee and o2h discovery plan to build a library of drug candidates against the lead target identified through OutSee’s precision medicine and genomic target discovery platform, Nomaly. Funding and support for the collaboration will be provided through o2h’s co-discovery InflexionTx model, which is designed to match-fund critical proof-of-concept studies at the HIT ID phase.
The seed round completes a financing first announced in June 2025 and was described as oversubscribed. Ahren Innovation Capital led the round, joined by Kadmos Capital, Panacea, Empirical Ventures and 26 angel investors. OutSee said the capital will support experimental validation of a broader set of targets generated by Nomaly, the buildout of an internal pipeline of assets, and ongoing R&D to enhance the platform and move from validation work toward active value generation.
OutSee positioned Nomaly as a “genomics-first” target identification approach built on hypothesis-free, predictive modelling. The company says the platform can generate disease and phenotype predictions directly from a single genome, and can be used alongside conventional discovery pipelines—including for smaller datasets or datasets that have already been analyzed through traditional methods.
The o2h discovery partnership marks OutSee’s first announced drug discovery programme tied to a lead target, with both parties aiming to combine OutSee’s computational biology capabilities with o2h’s integrated preclinical discovery platform to progress the programme toward future therapeutic development.
KEY QUOTES:
“Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery. The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team.”
Dr. Julian Gough, CEO and Founder, OutSee
“o2h discovery prioritises insight-driven science and OutSee’s pioneering approach to target identification facilitates just that, holding the potential to unlock a new wave of therapeutic targets. The technology is disruptive and enables datasets to be analysed in a completely new way, even those that have already been combed using traditional methods. We look forward to working together and leveraging our respective expertise to drive this programme forward.”
Prashant Shah, Co-founder, o2h Group
